Correspondence 0001654954-23-002981 from Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc.
Date: March 16, 2023 · CIK: 0001853816 · Accession: 0001654954-23-002981
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270195
Letter
Re:
drma-besteffortss1acceler
March 16, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Dermata Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-270195)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 3:00 p.m., Eastern Time, on March 16, 2023, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
Very
truly yours,
DERMATA
THERAPEUTICS, Inc.
Show Raw Text
CORRESP 1 filename1.htm drma-besteffortss1acceler March 16, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Dermata Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-270195) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 3:00 p.m., Eastern Time, on March 16, 2023, or as soon as practicable thereafter. Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, DERMATA THERAPEUTICS, Inc. By: /s/ Gerald T. Proehl Gerald T. Proehl Chief Executive Officer